These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29897725)

  • 21. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
    Gijsen VM; van Schaik RH; Soldin OP; Soldin SJ; Nulman I; Koren G; de Wildt SN
    Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I; Bremer S; Midtvedt K; Mohebi B; Dahl M; Bergan S; Åsberg A; Christensen H
    Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.
    Wang Z; Wu S; Chen D; Guo F; Zhong L; Fan J; Peng Z
    Eur J Clin Pharmacol; 2014 Aug; 70(8):925-31. PubMed ID: 24820765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
    Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
    Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period.
    Zhang X; Wang Z; Fan J; Liu G; Peng Z
    Eur J Clin Pharmacol; 2011 Aug; 67(8):803-13. PubMed ID: 21359536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
    Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
    Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
    Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
    Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.
    Tsuchiya N; Satoh S; Tada H; Li Z; Ohyama C; Sato K; Suzuki T; Habuchi T; Kato T
    Transplantation; 2004 Oct; 78(8):1182-7. PubMed ID: 15502717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
    Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
    Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
    Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
    Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus Starting Dose Prediction Based on Genetic Polymorphisms and Clinical Factors in Chinese Renal Transplant Recipients.
    Wang P; Zhang Q; Tian X; Yang J; Zhang X
    Genet Test Mol Biomarkers; 2020 Oct; 24(10):665-673. PubMed ID: 32985896
    [No Abstract]   [Full Text] [Related]  

  • 37. Influence of IL-18 and IL-10 Polymorphisms on Tacrolimus Elimination in Chinese Lung Transplant Patients.
    Zhang X; Xu J; Fan J; Zhang T; Li Y; Xie B; Zhang W; Lin S; Ye L; Liu Y; Jiang G
    Dis Markers; 2017; 2017():7834035. PubMed ID: 28246425
    [No Abstract]   [Full Text] [Related]  

  • 38. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
    Liu S; Chen RX; Li J; Zhang Y; Wang XD; Fu Q; Chen LY; Liu XM; Huang HB; Huang M; Wang CX; Li JL
    Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Genetic Polymorphism in CYP3A4 and CYP3A5 Genes on Tacrolimus Dose Among Kidney Transplant Recipients.
    Yousef AM; Qosa H; Bulatova N; Abuhaliema A; Almadhoun H; Khayyat G; Olemat M
    Iran J Kidney Dis; 2016 May; 10(3):156-63. PubMed ID: 27225724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.